MBX Biosciences, Inc.
Molecular by Evolution is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel precision peptide therapies for endocrine and metabolic disorders. The company was founded by global leaders in peptide drug design and development and operates its proprietary Precision… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What MBX Biosciences, Inc. does
In the company’s own words
Molecular by Evolution is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel precision peptide therapies for endocrine and metabolic disorders. The company was founded by global leaders in peptide drug design and development and operates its proprietary Precision Endocrine Peptide (PEP) platform, which is engineered to overcome key limitations of existing peptide therapies by optimizing pharmaceutical properties including extended time-action profiles, consistent drug concentrations with low peak-to-trough ratios, and less frequent dosing requirements.
The company's pipeline includes three primary programs. Canvuparatide, its lead product candidate, is a parathyroid hormone peptide prodrug designed as a long-acting hormone replacement therapy for chronic hypoparathyroidism, with Phase 2 trial results demonstrating achievement of primary endpoints and a planned Phase 3 initiation in the third quarter of 2026. The obesity portfolio includes MBX 4291, a long-acting GLP-1 and GIP receptor co-agonist prodrug designed for potential once-monthly dosing with improved efficacy and tolerability compared to existing treatments, currently in Phase 1 development with results expected in 2027. Imapextide, a long-acting GLP-1 receptor antagonist, is being developed for post-bariatric hypoglycemia as a potential once-weekly therapy, with Phase 2a results anticipated in the second quarter of 2026.
The PEP platform incorporates proprietary tools including innovative peptide design, programmable prodrug technologies, and fatty acylation to achieve extended duration of action and improved clinical outcomes. The company's scientific foundation builds upon expertise originally discovered at Indiana University's laboratory of a globally recognized endocrine pharmacology researcher.
Molecular by Evolution operates as a smaller reporting company and is classified as an emerging growth company. The company has not yet generated revenue from product sales and continues to incur significant losses as it advances its clinical development programs. The company estimates that chronic hypoparathyroidism affects approximately 120,000 people in the United States and more than 250,000 in the United States and Europe, while obesity affects an estimated 190 million adults in the United States who are obese or overweight.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- CARMEL, IN
- Fiscal year end
- December
- CIK
- 1776111
- SIC
- 2834
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns MBX Biosciences, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · MBX Biosciences, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do MBX Biosciences, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of MBX Biosciences, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in MBX Biosciences, Inc.'s last four quarterly filings that the numbers alone won't show?”